Opendata, web and dolomites

ImmunoFarm

IgA-based oral therapy for protection of piglets against infection with enterotoxigenic E. coli.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImmunoFarm project word cloud

Explore the words cloud of the ImmunoFarm project. It provides you a very rough idea of what is the project "ImmunoFarm" about.

siga    f18    antibody    arabidopsis    passive    rearing    enterotoxigenic    forbidden    anti    infections    benthamiana    phage    fight    etec    effect    synergistic    villus    additive    transformants    vivo    prophylaxis    receiving    neutralisation    genes    adhesion    diarrhoea    f4    host    scalable    biosafe    weaning    except    prolong    fimbriae    transferred    nicotiana    pwd    pig    format    performed    responsible    soya    abundance    coli    formulation    mucosal    thaliana    immunity    bulk    regular    engineered    pigs    negative    postweaning    transient    obtain    platform    elite    post    maternal    industry    expression    seed    oligoclonal    economic    cocktails    agent    group    feed    strategy    losses    world    antibiotics    global    formulations    assays    antibodies    piglets    seeds    immunotherapy    domains    illness    strains    resistance    vitro    lactogenic    prophylactic    display    vhhs    rest    groups    twenty    surfaces    first    predominantly    caused    treatment   

Project "ImmunoFarm" data sheet

The following table provides information about the project.

Coordinator
VIB 

Organization address
address: RIJVISSCHESTRAAT 120
city: ZWIJNAARDE - GENT
postcode: 9052
website: www.vib.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website https://www.facebook.com/ImmunoFarm-356855711413541/
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2017-08-13

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIB BE (ZWIJNAARDE - GENT) coordinator 160˙800.00

Map

 Project objective

Postweaning diarrhoea (PWD) in pigs is responsible for important economic losses in the global pig rearing industry. This illness is predominantly caused by enterotoxigenic E. coli strains carrying the F4 (ETEC-F4) and F18 (ETEC-F18) fimbriae. There is no treatment available to fight PWD except using antibiotics. However, the prophylactic use of antibiotics is forbidden in Europe and is expected to become forbidden in the rest of the world because of increasing abundance of resistance genes. Delivery of sIgA to mucosal surfaces as passive immunotherapy agent is a very promising strategy to prolong maternal lactogenic immunity against post-weaning infections. The aim of this project is to produce sIgA-like anti-ETEC antibodies in a cost-effective platform. Twenty different anti ETEC-F18 antibodies in a sIgA-like format will be engineered from phage display-selected variable domains (VHHs) currently available in the host institute. The synergistic or additive neutralisation effect of oligoclonal antibody cocktails will be evaluated using ETEC-F18 in vitro villus adhesion assays. The different antibodies will be produced first by transient expression in Nicotiana benthamiana and second in seeds of Arabidopsis thaliana transformants. An in vivo ETEC-F18 challenge will then be performed using two groups of piglets, one receiving the most effective seed-derived feed formulations and the other one receiving regular feed (negative control group). The sIgA antibodies of the elite oligoclonal formulation will then be transferred to biosafe soya seeds as production platform. These steps will lead towards the development of scalable procedures to obtain a cost effective bulk production of a feed based prophylaxis against ETEC.

 Publications

year authors and title journal last update
List of publications.
2016 Vikram Virdi, Paloma Juarez, Veronique Boudolf, Ann Depicker
Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles
published pages: 535-545, ISSN: 1420-682X, DOI: 10.1007/s00018-015-2074-0
Cellular and Molecular Life Sciences 73/3 2019-07-24
2016 Paloma Juarez, Vikram Virdi, Ann Depicker, Diego Orzaez
Biomanufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applications
published pages: n/a-n/a, ISSN: 1467-7644, DOI: 10.1111/pbi.12541
Plant Biotechnology Journal 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOFARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOFARM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MetAeAvIm (2019)

The Role of the Metabolism in Mosquito Immunity against Dengue virus in Aedes aegypti

Read More  

The Damned (2020)

Algeria, antifascism, and Third Worldism: An anticolonial genealogy of the Western European New Left (Algeria, France, Italy, 1957-1975)

Read More  

POSTBREXIT (2019)

The Brexit effect in media coverage: how the intra-party democracy counters the rise of European populism

Read More